By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Advaxis, Inc. 

The Technology Centre of New Jersey
675 U.S. Route One, South
North Brunswick  New Jersey  08902   U.S.A.
Phone: 732-545-1590 Fax: 732-545-1084


SEARCH JOBS

Advaxis is a clinical-stage biotechnology company developing cancer immunotherapies that enlist the body’s own immune system to fight cancer.

YEAR FOUNDED:

2002

LEADERSHIP:

CEO: Daniel O’Connor

CFO: Sara Bonstein

CSO (Scientific): Robert Petit

JOBS:

Please click here for Advaxis job opportunities.

CLINICAL TRIAL:

Please click here for clinical trial information.

FOLLOW ADVAXIS:



Key Statistics


Email:
Ownership: Public

Web Site: Advaxis
Employees:
Symbol: ADXS
 



Industry
Biotechnology






Company News
Advaxis (ADXS) To Host Investor & Analyst Day On June 12 5/18/2017 9:48:19 AM
Advaxis (ADXS) Provides Phase 1 Data of Higher Dose Axalimogene Filolisbac 5/15/2017 8:20:30 AM
Advaxis (ADXS) Appoints Anthony Lombardo As Chief Business Officer 4/19/2017 8:48:08 AM
Gazing Into The Crystal Ball For Advaxis (ADXS): What To Expect At ASCO 2017 4/7/2017 6:02:17 AM
Advaxis (ADXS) Provides Phase I Data Of Higher Dose Axalimogene Filolisbac 3/27/2017 7:12:42 AM
Advaxis (ADXS) Release: EMA Certification Paves The Way For The MAA Submission For Axalimogene Filolisbac In Metastatic Cervical Cancer 3/23/2017 11:29:44 AM
Advaxis (ADXS) Presents Oral Late-Breaking Data On Phase II GOG-0265 Study Of Axalimogene Filolisbac At SGO’s Annual Meeting On Women’s Cancer 3/15/2017 8:43:37 AM
Advaxis (ADXS) Appoints Al Blunt, M.D., As Its Vice President Of Medical 3/7/2017 8:56:56 AM
Advaxis (ADXS) Announces FDA Acceptance Of IND For Groundbreaking Personalized Neoepitope Immunotherapy, ADXS-NEO 3/6/2017 10:53:54 AM
Advaxis (ADXS), SELLAS Life Sci Ink $358 Million Cancer Immunotherapy R&D Pact 2/27/2017 6:42:19 AM
12345678910...
//-->